Drug intelligence / Profile preview

ZYH7

Development stage: Unknown
Lead developer: Zydus Lifesciences
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

ZYH7 is a novel small molecule drug developed as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. Its primary mechanism of action is the modulation of PPARα, which plays a key role in lipid metabolism. By activating PPARα, ZYH7 is expected to decrease triglyceride levels and correct dyslipidemia. The drug was conceptualized and developed by scientists at the Zydus Research Centre (Zydus Cadila Healthcare Ltd.), with clinical development led by Zydus Lifesciences Ltd. It has been investigated for the treatment of dyslipidemia and metabolic disorders such as hypertriglyceridemia, type 2 diabetes, obesity, and other related endocrine/metabolic diseases[1][2][3][6].

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on ZYH7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYH7.

Explore the full profile